Clinical Trials
The Type 1 Diabetes Prevention Trial (INIT II)
Professor Len Harrison and Professor Peter Colman have designed a nation-wide, ground-breaking trial to determine whether an intranasal insulin vaccine can prevent progression to type 1 diabetes in people at risk.The Type 1 Diabetes Prevention Trial, also known as the Intranasal Insulin Trial (INIT II) is seeking 13,000 relatives of people with type 1 diabetes who are aged between 4 and 30. They will be asked to have a blood test for pancreatic islet autoantibodies. This test can identify people with an increased risk of type 1 diabetes, many years before symptoms develop. Those with a positive test may be eligible to participate in the trial. Please speak to your patients with type 1 diabetes and encourage them to tell their relatives about the trial. For information please call 1300 138 712 or visit www.stopdiabetes.com.au.
2013 is the FINAL YEAR of recruitment for the type 1 diabetes prevention trial (INIT II).
The Diabetes Vaccine Development Centre (DVDC) URGENTLY needs your help to reach the trial recruitment target of 120 participants.
DVDC need to find relatives who are at ‘high risk’ of developing type 1 diabetes. Eligible relatives take a nasal spray vaccine aimed at preventing the development of type 1 diabetes.
To find these people we need blood tests from a minimum 12,240 relatives of people with type 1 diabetes. To date, DVDC have tested 8,327 people and now have 84 participants in the trial. We need 36 more RELATIVES of people with type 1 diabetes to be recruited.
For more information go to www.stopdiabetes.com.au or call 1300 138 712.
The trial is managed by the Diabetes Vaccine Development Centre and is supported by the National Health and Medical Research Council (NHMRC) and JDRF.
